Stock GLMD GALMED PHARMACEUTICALS LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Galmed Pharmaceuticals Ltd.

Equities

GLMD

IL0011313900

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-04-16 pm EDT 		5-day change 1st Jan Change
0.3543 USD -5.80% Intraday chart for Galmed Pharmaceuticals Ltd. -8.85% -22.13%
Apr. 04 Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Mar. 15 Galmed Pharmaceuticals Ltd. Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of Nash and Liver Fibrosis CI

Evolution of the average Target Price on Galmed Pharmaceuticals Ltd.

Price target over the last 5 years

History of analyst recommendation changes

d1b366137079bbfdf67038dfc4.uchoJxMT3vjnKPUYR2ck9MGvCOUivZ7wtNycqX0Ilpc.34QyVXJdnY3fQLZvAl9lnZfhetdXiOyS2bLoyBJGzNr3ki8XdCGYlKlOpA~bb925be91eae4380ae8f7230355eeb2c

Analyst Recommendations on Galmed Pharmaceuticals Ltd.

Maxim Upgrades Galmed Pharmaceuticals to Buy From Hold, Price Target is $4 MT
Maxim Group Downgrades Galmed Pharmaceuticals to Hold From Buy MT
Canaccord Genuity Downgrades Galmed Pharmaceuticals to Hold From Buy, Adjusts Price Target to $1 From $5 MT
Cantor Fitzgerald Downgrades Galmed Pharmaceuticals to Neutral From Overweight, Cuts Price Target to $0.70 From $5 MT
Galmed Pharmaceuticals Shares Fall After Rating Downgrade From Raymond James MT
Raymond James Downgrades Galmed Pharmaceuticals to Market Perform From Outperform MT
HC Wainwright Downgrades Galmed Pharmaceuticals to Neutral From Buy MT
Raymond James Adjusts Price Target on Galmed Pharmaceuticals to $5 From $14, Keeps Outperform Rating MT
GALMED PHARMACEUTICALS : HC Wainwright & Co. Adjusts Price Target on Galmed Pharmaceuticals to $25 From $29, Maintains Buy Rating MT
GALMED PHARMACEUTICALS : Canaccord Genuity Adjusts Price Target on Galmed Pharmaceuticals to $20 From $25, Maintains Buy Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.3761 USD
Average target price
1 USD
Spread / Average Target
+165.89%
High Price Target
1 USD
Spread / Highest target
+165.89%
Low Price Target
1 USD
Spread / Lowest Target
+165.89%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Galmed Pharmaceuticals Ltd.

Maxim
Canaccord Genuity
Cantor Fitzgerald
Raymond James
HC Wainwright

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. GLMD Stock
  4. Consensus Galmed Pharmaceuticals Ltd.